Edition:
United States

Lantheus Holdings Inc (LNTH.OQ)

LNTH.OQ on NASDAQ Stock Exchange Global Market

13.45USD
15 Aug 2018
Change (% chg)

$0.00 (+0.00%)
Prev Close
$13.45
Open
$13.45
Day's High
$13.60
Day's Low
$13.15
Volume
55,113
Avg. Vol
86,023
52-wk High
$24.45
52-wk Low
$12.85

Latest Key Developments (Source: Significant Developments)

GE Healthcare, Lantheus Starts A Phase 3 Clinical Trial Of Flurpiridaz
Tuesday, 31 Jul 2018 08:00am EDT 

July 31 (Reuters) - Lantheus Holdings Inc ::GE HEALTHCARE AND LANTHEUS ANNOUNCE START OF A PHASE 3 CLINICAL TRIAL OF FLURPIRIDAZ, AN INVESTIGATIONAL AGENT BEING EVALUATED FOR THE DETECTION OF CORONARY ARTERY DISEASE.GE HEALTHCARE AND LANTHEUS ANNOUNCE START OF A PHASE 3 CLINICAL TRIAL OF FLURPIRIDAZ, AN INVESTIGATIONAL AGENT BEING EVALUATED FOR THE DETECTION OF CORONARY ARTERY DISEASE.  Full Article

Lantheus Says NTP Radioisotopes Instituted Temporary Suspension Of Production Operations At Facility In South Africa
Wednesday, 6 Jun 2018 05:47pm EDT 

June 6 (Reuters) - Lantheus Holdings Inc ::LANTHEUS HOLDINGS - NTP RADIOISOTOPES INSTITUTED TEMPORARY SUSPENSION OF PRODUCTION OPERATIONS AT MOLYBDENUM-99 PROCESSING FACILITY IN SOUTH AFRICA.LANTHEUS HOLDINGS - NTP'S RESUMPTION OF OPERATIONS WILL DEPEND ON APPROVAL BY SOUTH AFRICAN NUCLEAR REGULATOR OF NTP'S REMEDIATION EFFORTS.LANTHEUS HOLDINGS INC SAYS UNIT RECEIVED NOTICE FROM NTP RADIOISOTOPES (SOC) LTD - SEC FILING.LANTHEUS HOLDINGS INC - MANAGEMENT IS NOT CHANGING ITS FINANCIAL GUIDANCE AT THIS TIME.LANTHEUS HOLDINGS - WILL WORK TO SOURCE ADDITIONAL MO-99 FROM OTHER SUPPLIERS DURING NTP'S CURRENT SUSPENSION OF OPERATIONS.  Full Article

Lantheus Holdings Reports Q4 Earnings Per Share $2.47
Monday, 26 Feb 2018 04:02pm EST 

Feb 26 (Reuters) - Lantheus Holdings Inc ::LANTHEUS HOLDINGS, INC. REPORTS 2017 FOURTH QUARTER AND FULL YEAR FINANCIAL RESULTS; PROVIDES 2018 GUIDANCE.Q4 EARNINGS PER SHARE $2.47.SEES FY 2018 REVENUE ABOUT $337 MILLION TO $342 MILLION.SEES Q1 2018 REVENUE $78 MILLION TO $83 MILLION.Q4 REVENUE ROSE 9.3 PERCENT TO $81.2 MILLION.‍Q4 2017 WORLDWIDE REVENUES OF $81.2 MILLION, A 9.3% INCREASE OVER PRIOR YEAR PERIOD​.  Full Article

Lantheus Holdings Says Lantheus Medical Entered Extension Of Supply Agreement With Jubilant Drax Images​
Friday, 5 Jan 2018 04:15pm EST 

Jan 5 (Reuters) - Lantheus Holdings Inc ::LANTHEUS HOLDINGS-ON DEC. 30, 2017, LANTHEUS MEDICAL ENTERED BINDING EXTENSION OF SUPPLY AGREEMENT WITH JUBILANT DRAX IMAGES,EFFECTIVE JAN. 1, 2018 ​.LANTHEUS HOLDINGS INC - ‍LMI WILL CONTINUE TO SUPPLY TRIAD WITH TECHNELITE GENERATORS, XENON, NEUROLITE AND OTHER PRODUCTS THROUGH 2020 - SEC FILING​.LANTHEUS HOLDINGS INC - ‍EXTENDED SUPPLY AGREEMENT WILL EXPIRE ON DECEMBER 31, 2020​.  Full Article

Lantheus Holdings reports Q3 earnings per share $0.22
Thursday, 2 Nov 2017 04:02pm EDT 

Nov 2 (Reuters) - Lantheus Holdings Inc :Lantheus Holdings Inc reports 2017 third quarter financial results; exceeds third quarter and raises full-year 2017 guidance.Q3 earnings per share $0.22.Q3 revenue $79.9 million versus I/B/E/S view $77.3 million.Sees fy 2017 revenue $323 million to $325 million.Q3 earnings per share view $0.21 -- Thomson Reuters I/B/E/S.Lantheus Holdings Inc - ‍increased its full-year 2017 guidance range for adjusted EBITDA to $86 million to $88 million from previous guidance of $82 million to $85 million​.Lantheus Holdings Inc - fy guidance for both revenue and adjusted EBITDA excludes impact of a $5.0 million up-front payment received in q2 of 2017 from GE Healthcare​.  Full Article

Lantheus Holdings Q2 earnings per share $0.35
Tuesday, 1 Aug 2017 04:02pm EDT 

Aug 1 (Reuters) - Lantheus Holdings Inc :Lantheus Holdings, Inc. reports 2017 second quarter financial results; exceeds second quarter and raises full-year 2017 guidance.Q2 earnings per share $0.35.Q2 revenue $88.8 million versus I/B/E/S view $80.6 million.Q2 earnings per share view $0.23 -- Thomson Reuters I/B/E/S.Sees Q3 2017 revenue $75 million to $78 million.Sees FY 2017 revenue $318 million to $322 million.Lantheus Holdings Inc - ‍increased its full-year 2017 guidance range for adjusted EBITDA to $82 million to $85 million​.Lantheus Holdings Inc - ‍for Q3 of 2017, company expects adjusted EBITDA in range of $17 million to $19 million​.Q3 revenue view $77.4 million -- Thomson Reuters I/B/E/S.FY2017 revenue view $317.3 million -- Thomson Reuters I/B/E/S.  Full Article

Lantheus Holdings sees Q2 revenue $79 mln-$82 mln
Tuesday, 2 May 2017 04:02pm EDT 

May 2 (Reuters) - Lantheus Holdings Inc :Lantheus Holdings, Inc. Reports 2017 first quarter financial results; exceeds first quarter and raises full-year 2017 guidance.Q1 earnings per share $0.11.Q1 revenue $81.4 million versus i/b/e/s view $78.2 million.Q1 earnings per share view $0.19 -- Thomson Reuters I/B/E/S.Q1 adjusted non-gaap earnings per share $0.28.Sees q2 2017 revenue $79 million to $82 million.Sees fy 2017 revenue $313 million to $318 million.Lantheus Holdings Inc - expects worldwide revenues in range of $79 million to $82 million for q2 of 2017.Lantheus Holdings Inc - for q2 of 2017, company expects adjusted ebitda in range of $18 million to $20 million.Lantheus Holdings Inc - guidance for both revenue and adjusted ebitda excludes impact of $5.0 million received from ge healthcare in april.Lantheus Holdings Inc - company has also increased its full-year 2017 guidance range for adjusted ebitda to $80 million to $83 million.Fy2017 revenue view $315.1 million -- Thomson Reuters I/B/E/S.  Full Article

Lantheus and GE Healthcare announce the signing of a definitive license agreement for worldwide development and commercialization of Flurpiridaz F 18
Tuesday, 25 Apr 2017 08:00am EDT 

April 25 (Reuters) - General Electric Co :Lantheus and GE Healthcare announce the signing of a definitive license agreement for worldwide development and commercialization of Flurpiridaz F 18.Lantheus Holdings - Under the agreement, GE Healthcare will lead and fund development program of Flurpiridaz F18, including second phase III clinical study.Lantheus Holdings says it will receive $5 million upfront cash payment and, if successful, up to $60 million in regulatory and sales milestones payments.  Full Article

Lantheus Holdings reports Q4 EPS $0.13
Tuesday, 21 Feb 2017 04:02pm EST 

Lantheus Holdings Inc : Reports 2016 fourth quarter and full year financial results; provides 2017 guidance . Q4 earnings per share $0.13 . Sees Q1 2017 revenue $77 million to $80 million . Sees FY 2017 revenue about $312 million to $317 million . Q4 revenue $74.4 million versus I/B/E/S view $70.8 million . Q4 earnings per share view $0.13 -- Thomson Reuters I/B/E/S . Says anticipates worldwide revenues for full year 2017 of approximately $312 million to $317 million, compared to $301.9 million in 2016 . Says for Q1 of 2017, company expects worldwide revenues in range of $77 million to $80 million . Anticipates full year 2017 adjusted ebitda of $79 million to $82 million . For Q1 of 2017 co expects adjusted EBITDA in range of $18 million to $20 million . Q4 revenue $74.4 million . FY2017 revenue view $312.2 million -- Thomson Reuters I/B/E/S .Q1 revenue view $77.8 million -- Thomson Reuters I/B/E/S.  Full Article

Lantheus Holdings & GE Healthcare announce the signing of a term sheet for worldwide development
Tuesday, 21 Feb 2017 04:00pm EST 

Lantheus Holdings Inc : Lantheus Holdings and GE Healthcare announce the signing of a term sheet for worldwide development and commercialization of flurpiridaz F 18 . Lantheus Holdings Inc - LMI would receive a $5 million upfront cash payment and, if successful, up to $60 million in regulatory and sales milestones payments . Lantheus Holdings Inc - GE Healthcare would fund second phase III flurpiridaz F 18 clinical study, worldwide regulatory approvals . Lantheus Holdings Inc - LMI would receive a usd 5 million upfront cash payment . Lantheus Holdings Inc - GE Healthcare would also fund flurpiridaz's worldwide launch and commercialization .Says parties anticipate entering into a definitive agreement for proposed transaction in Q2 of 2017.  Full Article